Kliogest N, film-coated tablets

( ARTG ) Short term symptomatic treatment of postmenopausal oestrogen deficiency (see DOSAGE AND ADMINISTRATION and CLINICAL TRIALS).‍‍‍‍‍‍​​​‍​​​​​​ For the prevention of postmenopausal bone mineral density loss. When prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. Life style modifications and the risk benefit profile of Kliogest should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. See PRECAUTIONS and DOSAGE AND ADMINISTRATION. Kliogest is for use in postmenopausal women with an intact uterus. In perimenopausal women treated with Kliogest the incidence of vaginal bleeding is unacceptably high and therefore therapy should not be initiated sooner than one year after the last menstrual period.